Aileron Therapeutics, Inc. announced the appointment of Hubert C. Chen, M.D., to Vice President of Clinical Development, Endocrine and Metabolic Disease.
FORMA Therapeutics announced the appointment of Rob Sarisky, Ph.D. to Chief Business Officer. Dr. Sarisky most recently served as Vice President of Oncology Business Development and Licensing at Janssen Pharmaceuticals.
Cerulean Pharma Inc. announced that the first patient has been dosed in a Phase 2 study of its lead candidate, CRLX101, in platinum-resistant ovarian cancer patients.
Receptos Inc. announced the co-publication, with The Scripps Research Institute, of high resolution G-protein coupled receptor (GPCR) crystal structures in Science. This will enable rational drug discovery and design of GPCRs.
Cerulean Pharma Inc. announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC) patients.
Cerulean Pharma Inc. announced the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin, in metastatic renal cell carcinoma (mRCC) patients.
FORMA Therapeutics and TGen Drug Development (TD2) announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both organizations.
Viamet Pharmaceuticals, Inc. announced that it has entered into a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Under this agreement, Viamet will utilize NIAID’s preclinical services program to develop broad-spectrum antifungal agents.
Protagonist entered into a collaboration agreement with Zealand Pharma to identify novel peptide drug candidates by utilizing Zealand Pharma’s expertise in peptide optimization technology.